Associations between statin treatment and markers of inflammation, vasoconstriction, and coagulation in patients with abdominal aortic aneurysm

Vascular and Endovascular Surgery

Volumn 42, Issue 6, 2009, Pages 567-573

  Gottsäter, Anders ^a,b   Flondell Site, Despina ^a   Kölbel, Tilo ^a   Lindblad, Bengt ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Abdominal aortic aneurysm; APC PCI complex; Homocysteine; Inflammation; Statins

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; CHOLESTEROL; ENDOTHELIN 1; GELATINASE A; GELATINASE B; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 3;

ABDOMINAL AORTA ANEURYSM; AGED; ANEURYSM RUPTURE; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; VASOCONSTRICTION;

AGED; AGED, 80 AND OVER; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; BLOOD COAGULATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; LOGISTIC MODELS; MALE; SEX FACTORS; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 58149103123     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574408320027     Document Type: Article

References (45)

1. Wassef M., Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg. 2001 ; 34: 730-738.
2. Vainas T., Lubbers T., Stassen F., et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation. 2003 ; 107: 1103-1105.
3. Norman P., Spencer CA, Lawrence-Brown MM, Jamrovik K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation. 2004 ; 110: 862-866.
4. Dawson J., Cockerhill GW, Choke E., Belli AM, Loftus I., Thompson MM Aortic aneurysms secrete interleukin-6 into the circulation. J Vasc Surg. 2007 ; 45: 350-356.
5. Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg. 2007 ; 45: 574-580.
6. Jones KG, Brull DJ, Brown LC, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation. 2001 ; 103: 2260-2265.
7. Satoh H., Nakamura M., Satoh M., et al. Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond). 2004 ; 106: 301-306.
8. Witkowska AM, Borawska MH, Gacko M. Relationship among TNF-alpha, sICAM-1, and selenium in presurgical patients with abdominal aortic aneurysms. Biol Trace Elem Res. 2006 ; 114: 31-40.
9. Kishimoto T. The biology of interleukin-6. Blood. 1989 ; 74: 1-10.
10. Schönbeck U., Libby P. CD40 signaling and plaque instability. Circ Res. 2001 ; 89: 1092-1103.
11. Schönbeck U., Gerdes N., Varo N., et al. Oxidized low-density lipoprotein augments and 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002 ; 106: 2888-2893.
12. Kälsch T., Nguyen XD, Elmas E., et al. Coagulation activation and expression of CD40 ligand on platelets in vitro liposaccharide-challenge in patients with unstable angina. Int J Cardiol. 2006 ; 111: 217-223.
13. Newby DE, Webb DJ The endothelin system in cardiovascular disease. Br Med J. 1997 ; 314: 531-532.
14. Ikeda U., Yamamoto K., Maeda Y., Shimpo M., Kanbe T., Shimada K. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 1997 ; 29: 65-69.
15. Yamazumi K., Ojiro M., Okumura H., Aikou T. An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm. Am J Surg. 1998 ; 175: 297-301.
16. Strandberg K., Kjellberg M., Knebel R., Lilja H., Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost. 2001 ; 86: 604-610.
17. Kölbel T., Strandberg K., Mattiasson I., Stenflo J., Lindblad B. Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms. J Vasc Surg. 2006 ; 43: 935-939.
18. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344: 1383-1389.
19. Downs JR, Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998 ; 279: 1615-1622.
20. Maron DJ, Fazio S., Linton MF Current perspectives on statins. Circulation. 2000 ; 101: 207-213.
21. Vaughan CJ, Gotto AM, Basson CT The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000 ; 35: 1-10.
22. Takemoto M., Liao JK Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1712-1719.
23. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. Non-lipid-related effects of statins. Ann Med. 2000 ; 32: 164-176.
24. Strandberg TE, Vanhanen H., Tikkanen MJ Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet. 1999 ; 353: 118-119.
25. Rosenson RS, Tangney CC, Casey LC Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999 ; 53: 983-984.
26. Ferro D., Parrotto S., Basili S., Alessandri C., Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol. 2000 ; 36: 427-431.
27. Ridker PM, Rifai N., Pfeffer MA, Sacks F., Braunwald E. ; for the Cholesterol and Recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999 ; 100: 230-235.
28. Undas A., Brumel-Zeidins KE, Mann KG Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005 ; 25: 287-294.
29. Masamura K., Oida K., Kanehara H., et al. Pravastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003 ; 23: 512-517.
30. Sukhija R., Aronow WS, Sandhu R., et al. Mortality and size of abdominal aortic aneurysm at long term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006 ; 97: 279-280.
31. Schouten O., van Laanen JH, Boersma E., Vidakovic R., Feringa HH, Dunkelgrun M. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006 ; 32: 21-26.
32. Evans J., Powell JT, Schwalbe E., Loftus IM, Thompson MM Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007 ; 34: 302-303.
33. Esmon CT The interactions between inflammation and coagulation. Br J Haematol. 2005 ; 131: 417-430.
34. Nieminen T., Knuuti J., Hämelahti P., et al. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vasc Pharmacol. 2007 ; 47: 113-117.
35. Moroz P., Le MT, Norman PE Homocysteine and abdominal aortic aneurysms. ANZ J Surg. 2007 ; 77: 329-332.
36. Halazun KJ, Bofkin KA, Asthana S., Evans C., Henderson M., Spark JI Hyperhomocysteinaemia is associated with the rate of abdominal aortic aneurysm expansion. Eur J Vasc Endovasc Surg. 2007 ; 33: 391-394.
37. Wagner A., Domanovits H., Holzer M., et al. Plasma endothelin in patients with acute aortic disease. Resuscitation. 2002 ; 53: 71-76.
38. Taeaka V., Wenham P., Valenta J., Topolcaan O., Pecen L. Plasma endothelin levels in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 1999 ; 17: 424-428.
39. Mraiche F., Cena J., Das D., Vollrath B. Effects of statins on vascular function of endothelin-1. Br J Pharmacol. 2005 ; 144: 715-726.
40. Lam HC, Chu CH, Wei MC, et al. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Biol Med. 2006 ; 231: 1010-1015.
41. AikawaM., RabkinE., SugiyamaS., etal. AnHMG-CoAreductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro. Circulation. 2001 ; 103: 276-283.
42. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G., Franklin DP, Youkey JR The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg. 1999 ; 29: 130-138.
43. Thompson RW, Baxter BT MMP inhibition in abdominal aortic aneurysms. Rrationale for a prospective randomized clinical trial. Ann N Y Acad Sci. 1999 ; 878: 159-178.
44. Nagashima H., Aoka Y., Sakomura Y., et al. Matrix metalloproteinase 2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg. 2004 ; 39: 447-453.
45. Crilly M., Bundred P., Hu X., Leckey L., Johnstone F. Gender differences in the clinical management of patients with angina pectoris: a cross-sectional survey in primary care. BMC Health Serv Res. 2007 ; 4: 142.